If you experienced serious side effects after taking Ozempic, such as stomach paralysis, intestinal blockages or sudden vision loss, you may have legal options. Learn more about the injuries linked to the drug, the status of Ozempic lawsuits and what to consider if you have been hurt by a GLP-1 medication.
See If You Qualify for an Ozempic Lawsuit Get a Free Case Review

Ozempic Lawsuits: Recent Updates

Some patients who experienced gastroparesis, intestinal blockages or sudden vision loss after taking Ozempic have filed lawsuits against Novo Nordisk. Those claims are being handled in federal court alongside other related GLP-1 drug cases, and additional state-court vision-loss cases have also been filed.

In December 2025, a federal panel combined 21 Ozempic and related GLP-1 vision loss lawsuits into a multidistrict litigation (MDL) in the Eastern District of Pennsylvania. As of June 2026, there were 86 cases pending in MDL-3163. MDLs allow similar cases to be bundled together in a single litigation to speed up the legal process.

These cases involve NAION (non-arteritic anterior ischemic optic neuropathy), a form of vision loss that usually affects one eye. It is typically permanent and people often first notice it when they wake up.

In February 2024, a federal panel combined 55 Ozempic and related GLP-1 lawsuits into a separate multidistrict litigation (MDL-3094) in the Eastern District of Pennsylvania. As of June 2026, there were 3,763 cases pending in the MDL. The litigation is still in its early stages, and there have not been any trials or settlements yet.

Ozempic and other GLP-1 litigation are still in their early stages, and no trials or settlements have been finalized.

Ozempic Lawsuit Timeline

  • May 20, 2026
    The FDA has received more than 207,000 adverse event reports related to Ozempic, Wegovy, Zepbound and Mounjaro, among the most popular of GLP-1 medications.
  • March 2026
    A federal court scheduled a “Science Day” for the Ozempic vision-loss cases on June 3, 2026. During the session, lawyers and medical experts are expected to present evidence to the judge.
  • December 15, 2025
    A separate federal multidistrict litigation was approved specifically for Ozempic blindness cases.
  • October 16, 2025
    The New Jersey Supreme Court approved consolidating gastroparesis and vision-loss lawsuits in two separate multicounty litigations (MCLs) in state court for faster handling.
  • December 2024
    The FDA’s adverse-event reporting system logged more than 88,000 complications from people taking Ozempic and similar GLP-1 drugs, including Mounjaro, Wegovy and Zepbound, since 2018.
  • November 2024
    The number of gastrointestinal lawsuits in the federal MDL grew 40% in two months, from 869 to 1,221 cases.
  • July 3, 2024
    A JAMA Ophthalmology study linked Ozempic to a higher risk of NAION, a condition that can cause sudden, typically permanent vision loss in one eye. Lawyers began investigating vision-loss claims in the wake of the study.
  • February 2, 2024
    A federal panel combined 55 lawsuits into a multidistrict litigation, a process that groups similar cases to move them through court more efficiently. The MDL covers Ozempic, Wegovy, Rybelsus, Mounjaro and Trulicity.
  • September 22, 2023
    The FDA added a warning about intestinal blockages, also called ileus, to Ozempic’s prescribing information.
  • March 28, 2022
    A JAMA Internal Medicine study found that higher doses and longer use of GLP-1 drugs were linked to an increased risk of gallbladder problems.
  • December 2021
    More than 7,800 side effect instances have been reported to the FDA for Ozempic, Mounjaro, Wegovy and Zepbound.

What Injuries Are Driving Ozempic Lawsuits?

Ozempic and related GLP-1 drugs have been linked to two main categories of serious injury in research and adverse-event reports.

The earliest Ozempic lawsuits focused on stomach paralysis (gastroparesis) and intestinal blockages (ileus). Patients often report severe nausea, vomiting that can last for weeks, abdominal pain and significant weight loss that they did not expect.

Vision loss (NAION) is the second main category. This rare condition can cause sudden and typically permanent vision loss in one eye. Research has suggested a link between semaglutide drugs and a higher risk of NAION.

What Stomach Paralysis and Ileus Look Like

Gastroparesis occurs when stomach muscles slow down or stop working, causing nausea, vomiting, bloating, abdominal pain, acid reflux, weight loss and appetite loss. There is no cure, though treatments may offer temporary relief.

Ileus similarly affects digestion, resulting in bloating, abdominal cramps, nausea, constipation, vomiting, difficulty passing gas and difficulty tolerating a regular diet.

Ozempic and Sudden Vision Loss (NAION)

A 2024 study in JAMA Ophthalmology found a link between semaglutide and NAION. Around 15% of people with NAION develop it in their other eye within five years. Vision loss from NAION is usually permanent. Researchers estimate that about 20% of patients see some improvement, but full recovery is rare.

The JAMA Ophthalmology study suggested people with obesity who take semaglutide for weight loss have more than seven times the risk of developing NAION compared to those who do not use it. People with Type 2 diabetes taking semaglutide have four times the risk.

NAION happens when blood flow to the optic nerve is blocked, and there is no cure. Researchers think GLP-1 drugs might affect the optic nerve and could lead to this eye condition.

Who Qualifies for an Ozempic Lawsuit?

You may qualify for a claim if you took Ozempic and then had serious stomach problems (like ongoing vomiting for four weeks or more, or stomach paralysis), intestinal blockage or sudden vision loss diagnosed as NAION.

Lawyers usually do not take cases from people who have had weight-loss surgery or are being treated for cancer, since these factors could explain the injuries in other ways.

Every state has different rules about who can file a claim, what proof you need and how long you have. In most places, you have three or four years to file, but some states only allow as little as one year. It’s important to speak to a lawyer right away.

Only a lawyer can tell you if you have a case. If you are thinking about making a claim, gather your medical records — these might include proof that you took Ozempic, when your symptoms began and how long they lasted, test results, or hospital records. Then talk to a lawyer or advocacy group about your next steps.

Did you or a loved one suffer from vision loss or severe gastroparesis after taking Ozempic?
Get your free case review today.

Case Study: Severe Gastroparesis With Ozempic and Mounjaro Use

Falisha Teague, 34, from Manchester, Kentucky, started using Ozempic and later Mounjaro to help manage Type 2 diabetes from March to December 2023. She developed gastroparesis, a condition where her stomach struggles to empty properly.

Injury and Symptoms

Teague had persistent nausea, vomiting of undigested food and abdominal pain, leading to severe dehydration and multiple emergency medical visits. She also experienced weight loss, malnutrition and chronic acid reflux.

Long-Term Impact on Health and Quality of Life

The gastroparesis diagnosis dramatically altered Teague’s life. She now depends on medical help to ease symptoms and is also handling treatment costs, all while trying to manage a chronic condition without a cure.

Do You Have a Case?

If you think your stomach problems or vision loss might be caused by a GLP-1 medication, Consumer Notice offers a free review to see if you might have a case. We work with top lawyers who handle Ozempic lawsuits to get the help you need. You do not have to file a lawsuit, and you only pay the lawyers if they win for you.

What an Ozempic Settlement Could Mean for You

A settlement is an agreement that ends a lawsuit without going to trial. As of June 2026, there have been no Ozempic settlements. The lawsuits are still in the early stages, and no trials have been completed. Any future settlements will depend on how the cases develop.

If a settlement is reached in the future, the amount someone might get depends on their unique case.

Factors That Can Affect Settlement Amounts
  • How serious the injury is
  • Your medical history
  • Medical bills
  • Lost income
  • Strength of the evidence that Ozempic caused the problem

Courts and lawyers also consider the number of people filing claims and any official reports on the drug when deciding settlement amounts.

Before accepting any settlement offer, talk to a lawyer. Only an attorney can explain if the offer covers your medical costs, future care, lost wages and other harms. They can help you determine whether the offer is fair and whether you should accept it.

What to Do Next

If you had stomach issues or vision loss after taking Ozempic, you can get a free case review. Consumer Notice can connect you with an experienced law firm to see if you qualify. There is no cost or obligation. Because legal deadlines are different in each state, reaching out to a lawyer as soon as you identify a problem can help ensure you don’t miss the window to file.

If you decide to move forward, your lawyer will explain your options. You can help by gathering your medical and prescription records. If you have urgent health problems, get medical care first — legal steps can wait until you are stable.

Did you or a loved one suffer from vision loss or severe gastroparesis after taking Ozempic?
Get your free case review today.

Please seek the advice of a qualified professional before making decisions about your health or finances.

Terry Turner
Written By Terry Turner Senior Writer

Terry Turner has been writing articles and producing news broadcasts for more than 30 years. An Emmy-winning journalist, he has reported on consumer policy issues before Congress, the Consumer Product Safety Commission, the Food and Drug Administration and other federal agencies.

Renée Deveney
Edited By Renée Deveney Senior Content Editor
Jonathan M. Sedgh, Esquire
Reviewed By Jonathan M. Sedgh, Esquire Mass Tort & Product Liability Attorney

Consumernotice.org adheres to the highest ethical standards for content production and references only credible sources of information, including government reports, interviews with experts, highly regarded nonprofit organizations, peer-reviewed journals, court records and academic organizations. You can learn more about our dedication to relevance, accuracy and transparency by reading our editorial policy.

  1. U.S. Food and Drug Administration. (2026, May 12). FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Retrieved from https://www.fda.gov/drugs/fda-adverse-event-monitoring-system-aems/fda-adverse-event-monitoring-system-aems-public-dashboard
  2. U.S. Judicial Panel on Multidistrict Litigation. (2026, May 12). MDL Statistics Report. Retrieved from https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-May-1-2026.pdf
  3. U.S. District Court for the Eastern District of Pennsylvania. (2026, March 16). Case Management Order No. 6 Science Day. Retrieved from https://www.paed.uscourts.gov/sites/paed/files/mdl-orders/25md3163_cm-ord_6.pdf
  4. U.S. Judicial Panel on Multidistrict Litigation. (2025, December 15). In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation; MDL No. 3163; Transfer Order. Retrieved from https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3163-Transfer_Order-12-25.pdf
  5. New Jersey Courts. (2025, October 16). Multicounty Litigation – Designation Of Litigation Involving GLP-1 Products Causing (1) Gastrointestinal Injuries And (2) Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Vision Loss As Separate MCLS. Retrieved from https://www.njcourts.gov/sites/default/files/notices/2025/11/n251112a.pdf?cb=245a6cff
  6. Brigham and Women’s Hospital. (2025). Non-Artertic Anterior Ischemic Optic Neuropathy (NAION). Retrieved from https://www.brighamandwomens.org/neurology/neuro-ophthalmology/non-arteritic-anterior-ischemic-optic-neuropathy
  7. National Library of Medicine. (2025). Ileus. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK558937/
  8. U.S. Food and Drug Administration. (2024, November 1). Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type
  9. U.S. District Court for the Eastern District of Pennsylvania. (2024, October 4). Teague v. Novo Nordisk; Complaint and Jury Demand, Civil Action No.: 2:24-Cv-5343. Retrieved from https://www.pacer.gov
  10. Hathaway, J.T. et al. (2024, July 3). Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Retrieved from https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255
  11. U.S. Judicial Panel on Multidistrict Litigation. (2024, February 2). Transfer Order, MDL No. 3094. Retrieved from https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3094-Transfer_Order-1-24.pdf
  12. U.S. District Court for the Eastern District of Pennsylvania. (2024). MDL 3094 in re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation. Retrieved from https://www.paed.uscourts.gov/mdl/mdl-3094-re-glucagon-peptide-1-receptor-agonists-glp-1-ras-products-liability-litigation
  13. U.S. Food and Drug Administration, (2023, September 22). Drug Safety-related Labeling Changes (SrLC); Ozempic. Retrieved from https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2183
  14. U.S. District Court Western District of Louisiana Lake Charles Division. (2023, September 9). Complaint and Demand for Jury Trial. Retrieved from https://clg.org/pdf/2/6/8/1/Complaint-Louisiana.pdf
  15. Lynch, J., et al. (2023, August 3). Woman Sues Drug Makers of Ozempic and Mounjaro Over Severe Gastrointestinal Issues. Retrieved from https://www.cnn.com/2023/08/03/business/ozempic-mounjoro-lawsuit/index.html
  16. Moniuszko, S. (2023, August 3). Ozempic, Mounjaro Manufacturers Sued Over Claims of “Stomach Paralysis” Side Effects. Retrieved from https://www.cbsnews.com/news/ozempic-mounjaro-lawsuit-gastroparesis-stomach-paralysis-side-effect/
  17. U.S. District Court Western District of Louisiana Lake Charles Division. (2023, August 2). Complaint and Demand for Jury Trial. Retrieved from https://www.forthepeople.com/sites/default/files/2023-08/Morgan%20%26%20Morgan%20Ozempic%20Bjorklund%20complaint%208.2.23.pdf
  18. UCI Health. (2023, July 28). In-Demand Weight-Loss Drugs Are No Magic Bullet, UCI Health Experts Say. Retrieved from https://www.ucihealth.org/news/2023/07/ozempic-wegovy-caution
  19. Goodman, B. (2023, July 25). They Took Blockbuster Drugs for Weight Loss and Diabetes. Now Their Stomachs Are Paralyzed. Retrieved from https://www.cnn.com/2023/07/25/health/weight-loss-diabetes-drugs-gastroparesis/index.html
  20. Burger, L. et al. (2023, July 10). EU Investigates Ozempic, Weight-Loss Drug Saxenda After Suicidal Thoughts Reported. Retrieved from https://www.reuters.com/business/healthcare-pharmaceuticals/eu-probes-novos-weight-loss-drugs-reports-suicide-risks-bloomberg-news-2023-07-10/
  21. Roberts, M. (2023, July 9). Weight-Loss Jabs Investigated for Suicide Risk. Retrieved from https://www.bbc.com/news/health-66119059
  22. Cleveland Clinic. (2023, July 3). GLP-1 Agonists. Retrieved from https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists
  23. Novo Nordisk. (2023, June 20). Press Release. Retrieved from https://www.novonordisk-us.com/media/news-archive/news-details.html?id=166121
  24. Ingram, D. (2023, June 15). More Than 4,000 Ads for Ozempic-Style Drugs Found Running on Instagram and Facebook. Retrieved from https://www.nbcnews.com/tech/internet/ozempic-weight-loss-drug-ads-instagram-wegovy-semaglutide-rcna88602
  25. He, L., et al. (2022, March 28). Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC8961394/
  26. U.S. Food and Drug Administration. (2022, March). Highlights of Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s009lbl.pdf
  27. Kalas, M.A., et al. (2021, October 18). Medication-Induced Gastroparesis: A Case Report. Retrieved from https://journals.sagepub.com/doi/10.1177/23247096211051919
  28. U.S. Food and Drug Administration. (2019, September). Highlights of Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf
  29. Morgan & Morgan. (n.d.). Morgan & Morgan Sues Ozempic® and Mounjaro™ Manufacturers. Retrieved from https://www.forthepeople.com/blog/morgan-morgan-sues-ozempicr-and-mounjarotm-manufacturers/